Mosquito control
Mosquito control encompasses systematic strategies to suppress populations of mosquitoes, which serve as vectors for diseases including malaria, dengue, Zika, chikungunya, and West Nile virus, thereby mitigating human health risks.[1][2] These strategies integrate source reduction by eliminating standing water breeding sites, chemical interventions such as larvicides and adulticides, biological agents like Gambusia fish that prey on larvae, and environmental management to disrupt mosquito life cycles.[3][4] Pioneered in the early 20th century, mosquito control achieved landmark successes with the advent of synthetic insecticides like DDT in the 1940s, which facilitated malaria elimination in the United States by 1951 through drainage, habitat modification, and targeted spraying.[5][6][7] DDT's indoor residual spraying proved highly effective in reducing malaria transmission, credited with saving millions of lives globally, though its widespread agricultural use prompted concerns over persistence in ecosystems and non-target effects, culminating in regulatory restrictions in many nations by the 1970s.[6][8][9] Contemporary efforts continue to yield progress, as evidenced by China's 2021 WHO certification as malaria-free following decades of vector surveillance, habitat control, and insecticide deployment.[10][11]Background and Importance
Global Disease Burden
Mosquitoes serve as primary vectors for multiple vector-borne diseases, accounting for the majority of the estimated 700,000 annual deaths from such illnesses worldwide, with malaria, dengue, and yellow fever comprising the heaviest toll.[12] These pathogens impose a disproportionate burden on tropical and subtropical regions, particularly sub-Saharan Africa and Southeast Asia, where underreporting due to limited surveillance in low-resource settings likely underestimates true incidence.[12] Malaria, transmitted primarily by Anopheles species, resulted in an estimated 263 million cases and 597,000 deaths globally in 2023, with over 95% of fatalities occurring in children under five in Africa.[13] This represents a stagnation in progress, as case numbers rose by 11 million from 2022 levels despite interventions, exacerbated by factors including insecticide resistance and disrupted health services.[14] Dengue fever, vectored by Aedes aegypti and Aedes albopictus, reached record levels in 2024 with over 14 million reported cases and approximately 10,000 to 12,000 deaths, a more than twofold increase from prior years driven by urbanization, climate variability, and viral serotype dynamics.[15] [16] Severe cases, characterized by hemorrhagic manifestations, disproportionately affect endemic areas in Asia and the Americas, though global surveillance gaps persist.[15] Yellow fever, also transmitted by Aedes species, causes an estimated 200,000 cases and 30,000 deaths annually, with 90% concentrated in Africa despite available vaccines; case-fatality rates exceed 50% in severe infections lacking supportive care. Outbreaks in the Americas, such as 61 confirmed cases with 30 deaths in 2024 across five countries, highlight ongoing risks from sylvatic cycles spilling into human populations.[17]| Disease | Primary Vector(s) | Estimated Annual Cases | Estimated Annual Deaths | Predominant Regions |
|---|---|---|---|---|
| Malaria | Anopheles spp. | 263 million (2023) | 597,000 (2023) | Sub-Saharan Africa |
| Dengue | Aedes aegypti, A. albopictus | >14 million (2024) | 10,000–12,000 (2024) | Asia, Americas |
| Yellow Fever | Aedes and Haemagogus spp. | 200,000 | 30,000 | Africa, South America |